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calculated deformation fields that can be applied to dose matrices. 
This allows us to accumulate the dose from one brachytherapy 
fraction to the next and will provide an improved estimate of the 
total dose delivered to the OAR. It should however be kept in mind 
that without a robust validation procedure,results could be very 
wrong in view of the very high dose gradients involved.The 
development of such a procedure should consequently be a 
prerequisite to any use of the deformation for brachytherapy in the 
clinic. 
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Purpose/Objective: The MR compatible Vienna (tandem-ring) and 
Utrecht applicator (tandem-ovoids) can be used for combined 
intracavitary (IC) and interstitial (IS) brachytherapy (BT) of locally 
advanced cervical cancer, with needles inserted through holes in the 
ring or ovoids. Recently a novel titanium Rotterdam applicator 
(tandem-ovoids) (Nucletron, Elekta) has been introduced which is well 
suited for MR guided IC BT of cervical cancer. This applicator has a 
fixed geometry and therefore enables fast and accurate applicator 
reconstruction. Currently the Rotterdam applicator does not include 
holes in the ovoids for needle positioning. The configuration of the 
holes restricts the possible locations and directions of needles. 
Therefore, the holes in the ovoids should be positioned such to allow 
optimal needle positioning for every patient. The purpose of this study 
is to determine the optimal configuration of the holes for needle 
positioning in the ovoids of the Rotterdam applicator making it 
suitable for combined IC/IS BT. 
Materials and Methods: A planning study was performed using MR 
datasets of 4 randomly chosen patients receiving IC BT for cervical 
cancer using the Rotterdam applicator. HR-CTV (range 1.2 – 57.5 cc), 
IR-CTV, rectum, sigmoid and bladder were delineated. The applicator 
was reconstructed with the aid of the applicator library file, a digital 
model of the applicator, present in the treatment planning system. 
For the IC treatment, without interstitial needles, modification of the 
standard treatment plan, that prescribes 7 Gy in points A, was 
necessary for all cases in order to restrict the dose to the OARs. The 
optimal position and direction of the ovoid holes for needle 
positioning was studied by adding virtual holes to the applicator 
library file at different locations and directions. This way treatment 
plans could be optimized for different needle (hole) configurations 
aiming at an increase of the dose to the HR-CTV while limiting the 
dose to the OARs. The configuration that yielded the best results 
among the 4 patients will be used as a blueprint for the holes in a 
prototype of the new applicator. 
Results: When using the IC applicator alone without needles, the dose 
in points A needed to be reduced from 7 Gy to 4.9 - 6.7 Gy. This 
resulted in a coverage of the delineated HR-CTV of (only) 66.5, 60.0, 
82.3 and 100.0 %, respectively, with a D90 HR-CTV of 4.9, 7.0, 5.9 and 
9.8 Gy. It turned out that a geometry allowing for insertion of 
maximally 3 needles per ovoid, each having an angle of 15º with the 
tandem in ventral-dorsal direction, resulted in a considerable increase 
of the D90 HR-CTV. For this geometry the coverage of the HR-CTV was 
88.1, 99.7, 98.6 and 100.0 %, respectively. The D90 HR-CTV was 6.7, 
9.5, 9.4 and 10.2 Gy. 
Conclusions: We have studied the optimal configuration of holes in 
the ovoids of the Rotterdam applicator for needle positioning for 
combined IC/IS treatment of locally advanced cervical cancer. A 
prototype of this new applicator is being build.  
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Purpose/Objective: The effect of bladder fullness on dose-volume 
parameters of OARs during the HDR intracavitary brachytherapy 
procedure with tandem-ovoid applicators and 192Ir source have been 
studied for cervical cancer patients who had complete response after 
EBRT. 
Materials and Methods: 17 patients with various cervical cancer 
stages with good remission of tumor after treating by 45-50 Gy 
external beam (there was no sign of residual tumor in taking MRIs 
after external beam treatment) took intracavitary Brachytherapy by 
Rotterdam Tandem-Ovoids applicators undergone two set of CT scans 
consecutively, one with filling the bladder by 120cc of normal saline 
solution and 3cc Meglumin compound and the other one with making 
the bladder as empty as possible, by trying to have no intended body 
motion during acquisitions. 3D image reconstruction has been done, 
and after that HR-CTV and OARs contouring applied, on the bases of 
GEC-ESTRO recommendations, for both CT sets. Finally 3D treatment 
planning has been achieved by the optimization capability of the 
software and exertion of manual corrections for dwell positions and 
times. 
Results: The volume of full and empty bladders was 166.5±26.4 and 
61.0±18.5, respectively. Paired samples T-test (P value=0.05) was 
used and the result have been indicated that there is no significant 
difference in D (2 cc), D (0.1 cc) and D (1 cc) of bladder, and also, D 
(2 cc) and D (0.1 cc) of rectum and sigmoid (p>0.05). Although, 
getting average of these dose parameters values respect to prescribe 
dose has shown a reduction for empty bladder condition. Mean 
Percentage Difference of CTV volumes were in the range of 0.00-0.08 
for two groups of contouring the patients CTs.  
 
 Mean value (percentage of prescribed dose)  
p-
value 
Empty bladder (%) Full bladder (%)   
0.098 74.2 82.7 
D (2cc) 
Bladder 
0.535 66.9 68.2 Rectum
0.830 46.8 47.4 Sigmoid
0.098 82.1 91.5 D (1cc) Bladder




0.264 89.4 93.0 Rectum
0.514 66.5 73.3 Sigmoid
0.330 96.9 94.5 D90 CTV 
Conclusions: Bladder filling had various influence on the position of 
bladder, cervix and uterus in respect to each other, corresponding to 
the various uterine anatomies (retroversion or anteversion) and 
posture of bladder relative to surrounding organs. The few 
discrepancies in CTV volume between two planning was due to 
considering GEC-ESTRO and ICRU recommendations in contouring HR-
CTVs and movement of OARs between these two patient anatomy 
conditions. Decrease in average of dose parameters for OARs and 
Increase in D90 for empty bladders can be a good motivation to 
choose this status although statistical test couldn’t improve it. Having 
two series of CT data in empty/full condition, at least for the first 
fraction of BT, can act as guidance and give a useful vision of 
anatomical reactions in each situation, but compromising with patient 
dose. Study is in progress for more case analysis.  
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Purpose/Objective: To objectively evaluate the implementation of 
MR Image Based Brachytherapy in Cervical Cancers at our centre.  
Materials and Methods: The approach consists of reporting the 
retrospective analysis of dosimetric and clinical outcome of 24 
patients (RD experience) with prescription to point A followed by 
prospective data (PD Experience) with HR-CTV dose optimization, 
prescription and contribution to multicentric International EMBRACE 
study. The dosimetric data (EQD2 values) and clinical outcome for 
these groups were compared and evaluated further with respect to 
